Rare Disease Biotech Xenon Pharmaceuticals Inc. Files For $52 Million IPO

Xenon Pharmaceuticals, an early-stage biotech with a gene therapy discovery platform for rare diseases, filed on Wednesday with the SEC to raise up to $52 million in an initial public offering. Xenon has a number of collaboration and licensing agreements with large pharmaceuticals including Teva, Genentech and Merck for its preclinical research.

The company's discovery platform was used to develop uniQure's Glybera treatment for lipoprotein lipase deficiency, the first gene therapy approved in the EU. February IPO uniQure ( QURE ) priced above its range but ended the first day down 14% and trades down 36%.

Help employers find you! Check out all the jobs and post your resume.